Studies unveil measures for reducing resistance to radiotherapy in tumors

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

FDA gives RaySearch green light for RayStation 8B platform First treatment planning system to offer machine learning applications

MedAustron to add health IT to proton and carbon ion treatment facilities Orders more than $13 million worth of RaySearch systems

'Nudge' in EHRs cuts imaging in half for palliative radiotherapy, says study Reduces duration of radiotherapy sessions

Mayo Clinic Florida campus to get $233 million proton facility The 140,000-square-foot facility will house a two-gantry proton system

Demand on the rise for MR-guided radiotherapy, says new report Compound annual growth rate of 20 percent through 2028

New proton therapy center planned in Russia Investment calls for 7.5 billion rubles to bring greater cancer care to patients

NYC proton facility opens for business $300 million dollar, 140,000 square-foot facility was ten years in the making

Bill aiming to reduce prior authorization delays for cancer treatment introduced in Congress Supporting timely access to care

Roche and GE Healthcare release NAVIFY Tumor Board 2.0 Supports personalized treatment decision-making

Cancer mortality for men, women and children on the decline, says report Decreased by 1.8 percent in men and 1.4 percent in women

A series of study have identified
potential ways for reducing resistance
within the immune system to
radiotherapy for fighting cancer cells

Studies unveil measures for reducing resistance to radiotherapy in tumors

John R. Fischer , Staff Reporter
A series of studies have outlined insights which may aid in reducing resistance within the immune system to radiation therapy for combating tumors.

The cause of such resistance in all three studies falls on Treg cells, immunosuppressant cells that prevent effector T cells from destroying healthy tissue. This function, however, also prevents the effector T cells killing cancer cells. Combined with other factors, the researchers found that reducing the amount of Tregs resulted in less resistance to radiotherapy, helping to make it a potent immunotherapeutic agent.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“The genomics and characteristics of the cancer cell still matter, but so does the surrounding tumor microenvironment,” Sana Karam, assistant professor of the department of radiation oncology at the University of Colorado, told HCB News. “In people, we are irradiating the cancer in its entirety and the effects will be on the tumor cells and other cells within the tumor. Some of these effects will be suppressive to the growth of cancer cells while others may not be. To be able to reach a point where we can talk about tumor eradication, we have to leverage the pros of radiation in suppressing tumor growth and overcome any tumor promoting properties.”

The stimulation of the immune system with radiotherapy to attack cancer cells throughout the body was first witnessed by radiation oncologists over a decade ago, prompting numerous attempts to replicate the actions and create systemic anti-cancer activity by combining radiotherapy with immunotherapy. Such attempts, however, have not been successful, even when employing triple therapy and different targeted strategies.

Alone, radiation therapy was not enough to destroy head and neck cancer models grown in mice in the first study. Treg depletion alone had the same outcome. When combined together, however, a potent reduction in tumors was observed, with radiation acting as stimulant that "turned on" the T effector cells of the immune system and enabled them to attack the cancer. The decrease in Tregs, meanwhile, prevented the cancer from "turning them off".

The approach is limited, due to there being no agent able to eradicate Tregs safely in humans. The study, however, may offer a possible solution by inhibiting communication between the proteins EphB4 and ephrinB2. Essential for neurogenesis in the developing brain, studies have revealed an up-regulation of both in various cancers, including head and neck, and pancreatic malignancies. Inhibiting the interaction between them reduces the growth of tumors, while depleting the number of T-regulatory cells.
  Pages: 1 - 2 >>

Rad Oncology Homepage


You Must Be Logged In To Post A Comment